JP2024534892A - 抗dll3抗体及びその使用 - Google Patents

抗dll3抗体及びその使用 Download PDF

Info

Publication number
JP2024534892A
JP2024534892A JP2024513940A JP2024513940A JP2024534892A JP 2024534892 A JP2024534892 A JP 2024534892A JP 2024513940 A JP2024513940 A JP 2024513940A JP 2024513940 A JP2024513940 A JP 2024513940A JP 2024534892 A JP2024534892 A JP 2024534892A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534892A5 (cg-RX-API-DMAC7.html
Inventor
ジョン ティー. ポワリエ,
チャールズ ルーディン,
ジェイソン ルイス,
アブドゥル カーン,
デイビッド アンドリュー,
シンレイ チェン,
イボ シー. ロレンツ,
キャスリン エム. タリー,
サロモン テンドラー,
Original Assignee
メモリアル スローン ケタリング キャンサー センター
スローン - ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
トライ-インスティテューショナル セラピューティクス ディスカバリー インスティテュート, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, スローン - ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ, トライ-インスティテューショナル セラピューティクス ディスカバリー インスティテュート, インコーポレイテッド filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2024534892A publication Critical patent/JP2024534892A/ja
Publication of JP2024534892A5 publication Critical patent/JP2024534892A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024513940A 2021-09-02 2022-09-02 抗dll3抗体及びその使用 Pending JP2024534892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240216P 2021-09-02 2021-09-02
US63/240,216 2021-09-02
PCT/US2022/042451 WO2023034566A1 (en) 2021-09-02 2022-09-02 Anti-dll3 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534892A true JP2024534892A (ja) 2024-09-26
JP2024534892A5 JP2024534892A5 (cg-RX-API-DMAC7.html) 2025-09-10

Family

ID=85412872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513940A Pending JP2024534892A (ja) 2021-09-02 2022-09-02 抗dll3抗体及びその使用

Country Status (7)

Country Link
US (1) US20240368269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534892A (cg-RX-API-DMAC7.html)
CN (1) CN118159558A (cg-RX-API-DMAC7.html)
AU (1) AU2022337142A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230628A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023034566A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202421189A (zh) * 2022-08-22 2024-06-01 美商雅博得樂醫療公司 用於標靶性放射性同位素療法之多價免疫結合物
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
WO2025061132A1 (en) * 2023-09-21 2025-03-27 Concept To Medicine Biotech Co., Ltd. Anti-dll3 antibodies and uses thereof
TW202600599A (zh) * 2024-03-11 2026-01-01 大陸商樂普生物科技股份有限公司 抗dll3抗體及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529656A (ja) * 2015-08-20 2018-10-11 アッヴィ・ステムセントルクス・エル・エル・シー 抗dll3抗体薬物コンジュゲートおよび使用方法
WO2019195408A1 (en) * 2018-04-03 2019-10-10 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
US20190375849A1 (en) * 2018-06-09 2019-12-12 Boehringer Ingelheim International Gmbh Multi-specific binding proteins for cancer treatment
WO2021007371A1 (en) * 2019-07-11 2021-01-14 Memorial Sloan Kettering Cancer Center Dll3-targeting antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2530091T3 (pl) * 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
EP2598532B1 (en) * 2010-07-30 2017-07-12 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
ES2886123T3 (es) * 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CN107922487A (zh) * 2015-03-06 2018-04-17 索伦托治疗有限公司 结合jag1的抗体治疗剂
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2019079762A1 (en) * 2017-10-20 2019-04-25 Children's National Medical Center METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM
AU2019414968A1 (en) * 2018-12-27 2021-08-12 Gigagen, Inc. Anti-PD-1 binding proteins and methods of use thereof
EP4065601A1 (en) * 2019-11-25 2022-10-05 Mabloc, LLC Anti-yellow fever virus antibodies, and methods of their generation and use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529656A (ja) * 2015-08-20 2018-10-11 アッヴィ・ステムセントルクス・エル・エル・シー 抗dll3抗体薬物コンジュゲートおよび使用方法
WO2019195408A1 (en) * 2018-04-03 2019-10-10 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
US20190375849A1 (en) * 2018-06-09 2019-12-12 Boehringer Ingelheim International Gmbh Multi-specific binding proteins for cancer treatment
WO2021007371A1 (en) * 2019-07-11 2021-01-14 Memorial Sloan Kettering Cancer Center Dll3-targeting antibodies and uses thereof

Also Published As

Publication number Publication date
CA3230628A1 (en) 2023-03-09
EP4396224A4 (en) 2025-11-12
AU2022337142A1 (en) 2024-03-07
US20240368269A1 (en) 2024-11-07
CN118159558A (zh) 2024-06-07
EP4396224A1 (en) 2024-07-10
WO2023034566A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
US20240368269A1 (en) Anti-dll3 antibodies and uses thereof
JP7661299B2 (ja) Dll3をターゲッティングする抗体とその使用
EP1470146B1 (en) Antibodies against the muc18 antigen
US7067131B2 (en) Methods for using anti-MUC18 antibodies
CN102137929B (zh) 用放射性同位素标记物标记的抗cdh3抗体及其用途
ES2460945T3 (es) Un anticuerpo monoclonal para CD44 para su uso en el tratamiento de carcinoma de células escamosas de cabeza y cuello
CA3069804A1 (en) Anti-cd166 antibodies and uses thereof
US20050118165A1 (en) Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
JP2010528056A (ja) がん細胞の細胞殺作用を媒介するヒト化抗trop−2抗体とキメラ抗trop−2抗体
TR201901824T4 (tr) Rs7 Antikorları
JP2010017189A (ja) 前立腺特異的膜抗原に対する修飾抗体およびその使用
MXPA04012656A (es) Anticuerpo hpam4 monoclonal humanizado.
AU2019321442A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CN101547936A (zh) 癌性疾病调节抗体
US20040136998A1 (en) Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
WO2024226646A2 (en) Dlk1 -targeting antibodies and uses thereof
JP2024533162A (ja) 抗cd33抗体及びその使用
WO2026083399A1 (en) Conjugates and use of same for theranostics
WO2025245299A1 (en) Methods of treating cancer with dll3 targeting radioimmunoconjugates
HK1175186A (en) A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260609